Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Acadia Healthcare Company Inc (ACHC) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance

Acadia Healthcare Company Inc
Amphastar Pharmaceuticals Inc

Price performance

Price movement over the last 24 hours

Key statistics

Acadia Healthcare Company Inc vs Amphastar Pharmaceuticals Inc — how do they compare? Acadia Healthcare Company Inc trades at $30.88 (market cap $2.94B), while Amphastar Pharmaceuticals Inc trades at $18.73 (market cap $885.83M). The key difference: Acadia Healthcare Company Inc is far larger — about 3.3× Amphastar Pharmaceuticals Inc's market cap, and Acadia Healthcare Company Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

ACHCAMPH
Market Cap
$2.94B$885.83M
Sector
HealthHealth
52-Week High
$31.92$30.81
52-Week Low
$11.68$16.87
Enterprise Value
$5.45B$1.28B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Acadia Healthcare Company Inc

ACHC trades at $31.09, down 2.57% today but maintains a bullish technical outlook with strong moving average support. The company shows operational strength with three consecutive earnings beats, though profitability remains challenged with a -32.84% net margin. Analyst consensus is strongly bullish with 68% buy ratings, while recent news highlights the company's strategic shift toward profitability and rising behavioral health demand.

The stock presents a mixed opportunity with strong technical momentum and analyst support offset by persistent profitability challenges. Key catalysts include continued earnings outperformance and successful execution of the turnaround strategy, while risks center on margin pressures and high short interest that could limit upside potential.

Amphastar Pharmaceuticals Inc

AMPH trades at $19.61, down 0.15% with a bearish technical outlook. The stock shows mixed fundamentals with a P/E of 11.81 and net margin of 11%, but recent earnings misses and declining 2026 profit projections raise concerns. Recent news includes a Zacks Strong Sell rating and a securities law investigation, while management focuses on transitioning to proprietary drugs for growth.

The outlook remains cautious with analyst consensus at Hold (66.7%) and a $20.40 price target offering limited upside. Key risks include earnings volatility, competitive pressures, and legal scrutiny. The stock presents moderate value but requires careful monitoring of execution on growth initiatives and upcoming Q2 earnings.

Returns comparison

Trailing returns across standard periods

About Acadia Healthcare Company Inc

Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.

Read more on ACHC

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH